Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study.
Apalutamide
Metastasis-free survival
Non-metastatic castration-resistant prostate cancer
Real-world data
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
09 Sep 2024
09 Sep 2024
Historique:
received:
31
05
2024
accepted:
16
08
2024
medline:
9
9
2024
pubmed:
9
9
2024
entrez:
9
9
2024
Statut:
epublish
Résumé
Apalutamide plus androgen-deprivation therapy (ADT) improved outcomes in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Nevertheless real-world data are limited. The aim of this multicenter study was to generate real-world data from nmCRPC patients treated with ADT plus apalutamide. In this observational cohort based investigator initiated trial data of nmCRPC patients receiving apalutamide plus ADT were collected focusing on patient demographic data, prostate-specific antigen (PSA) declines, safety profile including dose modification/discontinuation as well as subsequent therapy and metastasis-free survival (MFS). Data from a total of 31 nmCRPC patients were documented. Compared to the Phase III study Spartan real-world patients are older, showed a higher ECOG-PS and more aggressive tumors. In the cohort PSA decreased about 98.1%, 74% of patients showed a PSA decrease over 90% and 54.8% reached a PSA-level < 0.2ng/ml. Apalutamide was well tolerated in real world patients: adverse events occurred in 67.7% but were in the majority mild (≥ grade 3: 6.5%). Dose reduction was necessary in 38.7% and 32.2% discontinued apalutamide treatment. MFS was 43 months and majority of patients were subsequently treated with abiraterone. In real world more comorbid nmCRPC patients with a higher ECOG-PS and more aggressive tumors are treated with apalutamide plus ADT. Nevertheless efficacy results as well as side effects are similar in real-world compared to Spartan trial showing also a rapid, durable and deep PSA response with a median MFS of 43 months.
Identifiants
pubmed: 39249593
doi: 10.1007/s00432-024-05928-7
pii: 10.1007/s00432-024-05928-7
doi:
Substances chimiques
apalutamide
0
Thiohydantoins
0
Prostate-Specific Antigen
EC 3.4.21.77
Androgen Antagonists
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
414Informations de copyright
© 2024. The Author(s).
Références
Baboudjian M, Gauthé M, Barret E, Brureau L, Rocchi P, Créhange G, Dariane C, Fiard G, Fromont G, Beauval JB, Mathieu R, Renard-Penna R, Roubaud G, Ruffion A, Sargos P, Rouprêt M, Ploussard G (2022) How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer? Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ? Prog Urol 32:6S43-6S53. https://doi.org/10.1016/S1166-7087(22)00174-9
Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA (2020) Trial designs using real-world data: the changing landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf 29:1201–1212. https://doi.org/10.1002/pds.4932
doi: 10.1002/pds.4932
pubmed: 31823482
Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 72:1494–1503. https://doi.org/10.1158/0008-5472.CAN-11-3948
doi: 10.1158/0008-5472.CAN-11-3948
pubmed: 22266222
pmcid: 3306502
Crona DJ, Whang YE (2017) Androgen receptor-dependent and -independent mechanisms involved in prostate Cancer Therapy Resistance. Cancers (Basel) 9:67. https://doi.org/10.3390/cancers9060067
doi: 10.3390/cancers9060067
pubmed: 28604629
Dahm P, Kunath F (2020) Evidence-based medicine in urology. World J Urol 38:515–516. https://doi.org/10.1007/s00345-020-03139-6
doi: 10.1007/s00345-020-03139-6
pubmed: 32112241
Eichler HG, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, Humphreys A, Vamvakas S, Brun N, Rasi G (2021) Randomized controlled trials Versus Real World evidence: neither Magic nor myth. Clin Pharmacol Ther 109:1212–1218. https://doi.org/10.1002/cpt.2083
doi: 10.1002/cpt.2083
pubmed: 33063841
Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B (2019) Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 25:7448–7454. https://doi.org/10.1158/1078-0432.CCR-19-1050
doi: 10.1158/1078-0432.CCR-19-1050
pubmed: 31511295
Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F (2015) Metastatic prostate Cancer and the bone. Significance and Therapeutic Options. Eur Urol 68:850-858. doi:10.1016/j.eururo.2015.06.039
Hussain A, Jiang S, Varghese D, Appukkuttan S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Corman S (2022) Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States. BMC Cancer 22:304. https://doi.org/10.1186/s12885-022-09364-z
doi: 10.1186/s12885-022-09364-z
pubmed: 35317768
pmcid: 8939229
Katsuta M, Nobeyama Y, Hirafuku K, Tashiro K, Kimura T, Asahina A (2024) Characteristics of mild and severe apalutamide-related cutaneous adverse events in patients with prostate cancer: a review of the literature. J Dermatol 51:110–114. https://doi.org/10.1111/1346-8138.16972
doi: 10.1111/1346-8138.16972
pubmed: 37732499
Rönningås U, Holm M, Doveson S, Fransson P, Beckman L, Wennman-Larsen A (2022) Signs and symptoms in relation to progression, experiences of an uncertain illness situation in men with metastatic castration-resistant prostate cancer-A qualitative study. Eur J Cancer Care 31:e13592. https://doi.org/10.1111/ecc.13592
doi: 10.1111/ecc.13592
Saad F, Small EJ, Feng FY, Graff JN, Olmos D, Hadaschik BA, Oudard S, Londhe A, Bhaumik A, Lopez-Gitlitz A, Thomas S, Mundle SD, Chowdhury S, Smith MR (2022) Deep prostate-specific Antigen response following addition of apalutamide to Ongoing Androgen Deprivation Therapy and Long-Term Clinical Benefit in SPARTAN. Eur Urol 81:184–192. https://doi.org/10.1016/j.eururo.2021.11.020
doi: 10.1016/j.eururo.2021.11.020
pubmed: 34916086
Sánchez JC, Picola N, Rodriguez-Vida A, Costa M, Castañeda DM, Márquez MP, Rodriguez JM, Gaya JM, Bravo A, Buisan O, Servian P, Suarez JF, Felip MM, Caparrós MJR, Asensio AA, Vilaseca A (2023) Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients. Cancer Med 12:21969–21977. https://doi.org/10.1002/cam4.6769
doi: 10.1002/cam4.6769
pubmed: 38063364
pmcid: 10757138
Schad F, Thronicke A (2022) Real-world evidence-current developments and perspectives. Int J Environ Res Public Health 19:10159. https://doi.org/10.3390/ijerph191610159
doi: 10.3390/ijerph191610159
pubmed: 36011793
pmcid: 9408280
Scher HI, Solo K, Valant J, Todd MB, Mehra M (2015) Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS ONE 10:e0139440–e0139440. https://doi.org/10.1371/journal.pone.0139440
doi: 10.1371/journal.pone.0139440
pubmed: 26460686
pmcid: 4603789
Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS (2005) Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918–2925. https://doi.org/10.1200/JCO.2005.01.529
doi: 10.1200/JCO.2005.01.529
pubmed: 15860850
Smith MR, Cook R, Lee KA, Nelson JB (2011) Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 117:2077–2085. https://doi.org/10.1002/cncr.25762
doi: 10.1002/cncr.25762
pubmed: 21523719
Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800–3806. https://doi.org/10.1200/JCO.2012.44.6716
doi: 10.1200/JCO.2012.44.6716
pubmed: 24043751
pmcid: 3795889
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ, SPARTAN Investigators (2018) Apalutamide Treatment and Metastasis-free survival in prostate Cancer. N Engl J Med 378:1408–1418. https://doi.org/10.1056/NEJMoa1715546
doi: 10.1056/NEJMoa1715546
pubmed: 29420164
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, Rooney B, Lopez-Gitlitz A, Small EJ (2021) Apalutamide and overall survival in prostate Cancer. Eur Urol 79:150–158. https://doi.org/10.1016/j.eururo.2020.08.011
doi: 10.1016/j.eururo.2020.08.011
pubmed: 32907777